Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
14/08/2023
Castrejon I, Molina J, Perez-Garcia C, Vela-Casampere P, Diaz-Torne C, Bohorquez C, Blanco-Madrigal J, Sanchez-Alonso F
ACR 2022
Castrejon I, Molina J, Perez-Garcia C, Vela-Casampere P, Diaz-Torne C, Bohorquez C, Blanco-Madrigal J, Sanchez-Alonso F. Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/cancer-risk-in-patients-with-rheumatic-diseases-exposed-to-different-biologic-and-targeted-synthetic-dmards-in-real-world-clinical-practice-data-from-biobadaser/
https://acrabstracts.org/abstract/cancer-risk-in-patients-with-rheumatic-diseases-exposed-to-different-biologic-and-targeted-synthetic-dmards-in-real-world-clinical-practice-data-from-biobadaser/